These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 23982433)

  • 21. Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen.
    Ramirez-Ardila DE; Helmijr JC; Look MP; Lurkin I; Ruigrok-Ritstier K; van Laere S; Dirix L; Sweep FC; Span PN; Linn SC; Foekens JA; Sleijfer S; Berns EM; Jansen MP
    Breast Cancer Res Treat; 2013 May; 139(1):39-49. PubMed ID: 23592373
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The High Frequency of PIK3CA Mutations in Iranian Breast Cancer Patients.
    Azizi Tabesh G; Izadi P; Fereidooni F; Emami Razavi AN; Tavakkoly Bazzaz J
    Cancer Invest; 2017 Jan; 35(1):36-42. PubMed ID: 27901576
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer.
    Chandarlapaty S; Sakr RA; Giri D; Patil S; Heguy A; Morrow M; Modi S; Norton L; Rosen N; Hudis C; King TA
    Clin Cancer Res; 2012 Dec; 18(24):6784-91. PubMed ID: 23092874
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PIK3CA mutational status in tissue and plasma as a prognostic biomarker in HR+/HER2- breast cancer.
    Terán E; Lozano R; Rodríguez CA; Abad M; Figuero L; Muñoz JA; Cigarral B; Rodrígues A; Sancho M; Gómez MA; Morchón D; Montero JC; Sayagués JM; Ludeña MD; Fonseca E
    Cancer Med; 2024 Sep; 13(17):e70101. PubMed ID: 39235099
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysing the mutational status of PIK3CA in circulating tumor cells from metastatic breast cancer patients.
    Schneck H; Blassl C; Meier-Stiegen F; Neves RP; Janni W; Fehm T; Neubauer H
    Mol Oncol; 2013 Oct; 7(5):976-86. PubMed ID: 23895914
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PIK3CA mutations in endometrial carcinomas in Chinese women: phosphatidylinositol 3'-kinase pathway alterations might be associated with favorable prognosis.
    Dong Y; Yang X; Wong O; Zhang X; Liang Y; Zhang Y; Wong W; Nong L; Liao Q; Li T
    Hum Pathol; 2012 Aug; 43(8):1197-205. PubMed ID: 22209294
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Different associations of tumor PIK3CA mutations and clinical outcomes according to aspirin use among women with metastatic hormone receptor positive breast cancer.
    McCarthy AM; Kumar NP; He W; Regan S; Welch M; Moy B; Iafrate AJ; Chan AT; Bardia A; Armstrong K
    BMC Cancer; 2020 Apr; 20(1):347. PubMed ID: 32326897
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Opposite Prognostic Impact of Single PTEN-loss and
    Lazaridis G; Kotoula V; Vrettou E; Kostopoulos I; Manousou K; Papadopoulou K; Giannoulatou E; Bobos M; Sotiropoulou M; Pentheroudakis G; Efstratiou I; Papoudou-Bai A; Psyrri A; Christodoulou C; Gogas H; Koutras A; Timotheadou E; Pectasides D; Zagouri F; Fountzilas G
    Cancer Genomics Proteomics; 2019; 16(3):195-206. PubMed ID: 31018950
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PIK3CA mutations in Peruvian patients with HER2-amplified and triple negative non-metastatic breast cancers.
    Castaneda CA; Lopez-Ilasaca M; Pinto JA; Chirinos-Arias M; Doimi F; Neciosup SP; Rojas KI; Vidaurre T; Balko JM; Arteaga CL; Gomez HL
    Hematol Oncol Stem Cell Ther; 2014 Dec; 7(4):142-8. PubMed ID: 25467032
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mucinous breast carcinomas lack PIK3CA and AKT1 mutations.
    Kehr EL; Jorns JM; Ang D; Warrick A; Neff T; Degnin M; Lewis R; Beadling C; Corless CL; Troxell ML
    Hum Pathol; 2012 Dec; 43(12):2207-12. PubMed ID: 22705004
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alterations in p53, BRCA1, ATM, PIK3CA, and HER2 genes and their effect in modifying clinicopathological characteristics and overall survival of Bulgarian patients with breast cancer.
    Bozhanov SS; Angelova SG; Krasteva ME; Markov TL; Christova SL; Gavrilov IG; Georgieva EI
    J Cancer Res Clin Oncol; 2010 Nov; 136(11):1657-69. PubMed ID: 20177704
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PIK3CA mutations rarely demonstrate genotypic intratumoral heterogeneity and are selected for in breast cancer progression.
    Kalinsky K; Heguy A; Bhanot UK; Patil S; Moynahan ME
    Breast Cancer Res Treat; 2011 Sep; 129(2):635-43. PubMed ID: 21617917
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mutational hotspot in exon 20 of PIK3CA in breast cancer among Singapore Chinese.
    Liang X; Lau QC; Salto-Tellez M; Putti TC; Loh M; Sukumar S
    Cancer Biol Ther; 2006 May; 5(5):544-8. PubMed ID: 16582596
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Changes in PIK3CA mutation status are not associated with recurrence, metastatic disease or progression in endocrine-treated breast cancer.
    Arthur LM; Turnbull AK; Renshaw L; Keys J; Thomas JS; Wilson TR; Lackner MR; Sims AH; Dixon JM
    Breast Cancer Res Treat; 2014 Aug; 147(1):211-9. PubMed ID: 25104442
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer.
    Loi S; Michiels S; Lambrechts D; Fumagalli D; Claes B; Kellokumpu-Lehtinen PL; Bono P; Kataja V; Piccart MJ; Joensuu H; Sotiriou C
    J Natl Cancer Inst; 2013 Jul; 105(13):960-7. PubMed ID: 23739063
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phosphatidylinositol 3-kinase (PI3KCA) oncogene mutation analysis and gene expression profiling in primary breast cancer patients.
    Kandula M; Chennaboina KK; Ys AR; Raju S
    Asian Pac J Cancer Prev; 2013; 14(9):5067-72. PubMed ID: 24175777
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Breast Cancer Heterogeneity Examined by High-Sensitivity Quantification of PIK3CA, KRAS, HRAS, and BRAF Mutations in Normal Breast and Ductal Carcinomas.
    Myers MB; Banda M; McKim KL; Wang Y; Powell MJ; Parsons BL
    Neoplasia; 2016 Apr; 18(4):253-63. PubMed ID: 27108388
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Secondary Analysis of the BIG 1-98 Randomized Clinical Trial.
    Luen SJ; Asher R; Lee CK; Savas P; Kammler R; Dell'Orto P; Biasi OM; Demanse D; JeBailey L; Dolan S; Hackl W; Thuerlimann B; Viale G; Colleoni M; Regan MM; Loi S
    JAMA Oncol; 2018 Oct; 4(10):1335-1343. PubMed ID: 29902286
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PIK3CA-AKT pathway mutations in micropapillary breast carcinoma.
    Flatley E; Ang D; Warrick A; Beadling C; Corless CL; Troxell ML
    Hum Pathol; 2013 Jul; 44(7):1320-7. PubMed ID: 23352210
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data.
    Zardavas D; Te Marvelde L; Milne RL; Fumagalli D; Fountzilas G; Kotoula V; Razis E; Papaxoinis G; Joensuu H; Moynahan ME; Hennessy BT; Bieche I; Saal LH; Stal O; Iacopetta B; Jensen JD; O'Toole S; Lopez-Knowles E; Barbaraeschi M; Noguchi S; Azim HA; Lerma E; Bachelot T; Wang Q; Perez-Tenorio G; Can de Velde CJH; Rea DW; Sabine V; Bartlett JMS; Sotiriou C; Michiels S; Loi S
    J Clin Oncol; 2018 Apr; 36(10):981-990. PubMed ID: 29470143
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.